Both type I and type II diabetes are characterised by a progressive decrease in beta-cell function and mass. In type I diabetes, autoimmune destruction results in rapid loss of beta-cell function, and insulin therapy is essential to maintain normoglycaemia. In type II diabetes, a diminished or absent first-phase insulin release is the earliest metabolic defect, which is accompanied by lack of prandial suppression of hepatic glucose production, increased postprandial glucose excursions and late insulin hypersecretion. Furthermore, chronic exposure to elevated glucose, even to intermittent postprandial spikes, results in further deterioration of the beta-cell function ('glucotoxicity'). By the time type II diabetes is diagnosed, beta-cell function and mass have declined by about 50%. With the progression of the disease and glucotoxicity there is continuous decrease in beta-cell mass due to increased apoptosis that results in absolute insulin deficiency. By then, patients require insulin administration to maintain glucose control. An increasing body of evidence demonstrates the importance of preserving endogenous beta-cell function both in type I and type II diabetes. Early and intensive glycaemic control, using regimens which re-create a physiological insulin profile, controlling postprandial as well as fasting glucose levels, offers the most promise for preserving beta-cell function, decreasing disease progression, and reducing the chronic complications of diabetes.
Introduction
Insulin plays a critical role in glucose homeostasis through regulation of hepatic glucose production, stimulation of peripheral glucose uptake by insulin-sensitive tissues, and prevention of excessive postprandial glucose excursions, without causing hypoglycaemia. The beta cell accomplishes this balancing act by carefully matching insulin secretion with blood glucose levels via continuous low level insulin secretion between meals (basal secretion) and intense short bursts in response to meals (prandial secretion) 1 ( Figure 1 ). The rapid insulin response at mealtime is particularly important because it ensures prompt inhibition of endogenous glucose production by the liver, and then the disposal of the mealtime carbohydrate load, limiting postprandial glucose excursions. 2 Early return of glycaemic levels to normal after a meal prevents late hyperinsulinaemia and prolonged secretory stress on the beta cells.
Type I and type II diabetes are both diseases of insulin deficiency and beta-cell failure
In type I diabetes, autoimmune destruction of beta cells results in severe insulin deficiency, and these patients require daily insulin replacement. In type II diabetes, the beta-cell loss is not as marked initially but it follows an inevitable and progressive decline. Before the onset of type II diabetes, many years of insulin resistance lead to compensatory insulin hypersecretion that seems to predispose to beta-cell dysfunction. Patients with impaired glucose tolerance (IGT) have a decrease or loss of the early mealtime insulin secretion with postprandial hyperglycaemia. The advance from IGT to frank diabetes is accompanied by progressive deterioration of beta-cell function that eventually leads to fasting hypergylcaemia. Type II diabetes requires decreases in both insulin secretion and insulin sensitivity. Many individuals with insulin resistance never develop diabetes as long as beta-cell secretion continues to compensate for it. 3 The onset of IGT and type II diabetes is marked by beta-cell dysfunction. 4, 5 Loss of the compensatory hypersecretion of insulin has been implicated as the turning point in the progression towards hyperglycaemia. 2 By the time type II diabetes is diagnosed, early insulin release has decreased by about 50% 6 and betacell function is reduced by a similar degree.
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Role of insulin deficiency vs insulin resistance in type II diabetes
The natural history of insulin secretory dysfunction and insulin resistance was studied longitudinally in Pima Indians, a population with a naturally high incidence of type II diabetes. 5 Among the individuals who 'progressed' to hyperglycaemia, early insulin secretion decreased by 27% from normal glucose tolerance (NGT) to IGT, and decreased an additional 51% from IGT to type II diabetes. In contrast, the acute insulin secretory response actually increased over time in the nonprogressors ( Figure 2 ). In the San Antonio metabolism (SAM) study, the relationship between insulin resistance and beta-cell function was examined in a Mexican-American population, another group with both a high level of insulin resistance and increased incidence of type II diabetes. The study evaluated insulin response and insulin sensitivity following an oral glucose challenge in 388 individuals with a wide range of glucose tolerance (baseline fasting plasma glucose (FPG) o5.0 to FPG 412.0 mmol/l). 8 Subjects classified as having IGT had a severely impaired plasma insulin response, suggesting that the onset of beta-cell dysfunction begins early in the natural history of type II diabetes, starting before the onset of biochemically apparent IGT. The key point in this study was that both beta-cell dysfunction and insulin resistance were already well established in individuals classified as having NGT. 8 Similar results were obtained in a 10-year prospective study of the natural history of type II diabetes in 432 newly diagnosed patients. 9 In this study, beta-cell function deteriorated progressively over a 6-year period, despite the absence of any consistent decline in insulin sensitivity. These and other studies have established that, in type II diabetes, beta-cell dysfunction begins many years before the development of IGT or hyperglycaemia, and that progression from IGT to overt type II diabetes is associated with a decline in beta-cell function with little increase in peripheral insulin resistance.
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Prandial insulin deficit
The earliest metabolic defect observed in people who transition from NGT to IGT is mild postprandial hyperglycaemia, 10 and as IGT progresses towards diabetes, postprandial hyperglycaemic excursions become more elevated and prolonged. Treatments that focus on normalising FPG may not adequately control postprandial glucose excursions. This is of concern because it is now well established that isolated postprandial hyperglycaemia greatly increases the risk of macrovascular disease, and can double the risk of mortality from cardiovascular disease. 11, 12 In the DECODE study, elevated postprandial glucose was associated with an increased risk of mortality from cardiovascular disease in subjects with a 2-h OGTT plasma glucose of 11.1 mmol/l or greater, compared with subjects with 2-h OGTT o7.8 mmol/l. FPG was not a statistically significant predictor of mortality when postprandial hyperglycaemia was accounted for in multivariate analysis. 12 Excessive postprandial glucose excursions may elevate HbA 1c levels, even when fasting blood glucose levels are well controlled. 13 Indeed, the third National Health and Nutrition Examination Survey reported that 39% of patients with type II diabetes who were not currently using insulin and who had HbA 1c o7.0% had postprandial hyperglycaemia (411.1 mmol/l) despite average fasting glucose concentrations o6.7 mmol/l in this group overall. 14 The prandial abnormalities in patients with type II diabetes include an early deficit in insulin secretion, which results in lack of suppression of hepatic glucose output and increased postprandial glucose excursions, followed by late insulin hypersecretion. 15 The delayed postprandial hyperinsulinaemia frequently observed in patients with mild type II diabetes or IGT is likely to be the consequence of hyperglycaemia secondary to an inadequate early response rather than peripheral insulin resistance. 15 The result is a nonphysiological sustained secretory stress on beta cells. Patients with type II diabetes show a marked disruption of insulin secretion after a meal, with both the increase and decrease in insulin secretion so sluggish that it was not always possible to clearly identify the prandial response following the evening meal.
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Decreased beta-cell mass in type II diabetes
In type I diabetes, beta-cell volume is reduced by about 80% before overt diabetes develops. 16 The limited existing data on beta-cell mass in type II diabetes are inconsistent, with some studies suggesting decreases 16, 17, 18 and others indicating that mass remains unchanged. 19, 20 In a study performed on patients who died at the Mayo Clinic, relative beta-cell volume, a surrogate for beta-cell mass, and apoptosis were evaluated using well-preserved pancreatic tissue from nondiabetic subjects, as well as those with impaired fasting glucose or type II diabetes. 21 Histological examination revealed that relative beta-cell volume was increased in obese nondiabetic patients, and decreased by 40% in patients with impaired fasting glucose and 63% in patients with type II diabetes. Beta-cell replication was low overall, and did not differ among the various groups, but the frequency of apoptosis was increased 10-fold in lean, and three-fold in obese patients with type II diabetes compared with nondiabetic controls.
Preserving beta-cell mass preserves beta-cell function
The ability to secrete adequate amounts of insulin is determined by the functional integrity of beta cells as well as their overall mass. 22 Regulation of beta-cell mass involves a balance between apoptosis and replication, as well as development of new islets from exocrine pancreatic ducts ('Neogenesis'). 23 In prediabetic conditions, such as obesity with insulin resistance, beta cells proliferate in response to increased demand for insulin, a function which appears to be lost as glucose tolerance deteriorates. The Mayo Clinic study provided the first evidence linking decreased beta-cell mass with functional deficits, and suggested that in type II diabetes, reductions in mass due to increased apoptosis may play an important role in the functional deficits observed. Given these data, it makes sense to consider strategies to prolong or preserve beta-cell function in both type I and type II diabetes.
Patients with type I diabetes rapidly lose insulin secretion as a result of autoimmune destruction of pancreatic beta cells. In the Diabetes Control and Complications Trial, patients classified initially as C-peptide responders and nonresponders were randomised to either conventional therapy or intensive therapy. C-peptide responders receiving intensive therapy maintained a higher stimulated C-peptide level and had a lower likelihood of becoming nonresponders than did those receiving conventional therapy (Figure 3 ). Cpeptide responders also had lower HbA 1c , reduced risk of retinopathy progression, and reduced risk for severe hypoglycaemia. The conclusion was that intensive therapy for type I diabetes helps sustain endogenous insulin secretion. 24 Similar results have been obtained looking at intensive control in patients with type II diabetes. Beta-cell function and glycaemic control were monitored over 2 years in 39 patients randomised to either two daily injections of premixed insulin (30% soluble human insulin and 70% NPH insulin), or the oral sulphonylurea glibenclamide. 25 Cpeptide-glucagon tests were performed yearly, in duplicate, after 2-3 days of temporary withdrawal of treatment. After 1 year, the glucagon-stimulated C-peptide response was increased in the insulin-treated group and decreased in the group that received glibenclamide. After 2 years, fasting insulin levels were higher in the insulin-treated group, and HbA 1c had deteriorated in the glibenclamide group.
Early and intensive insulin treatment limits glucotoxicity
'Glucotoxicity' has been defined as nonphysiological, irreversible alterations in cellular function caused by chronic exposure to high glucose concentrations. 26 Glucotoxicity affects many peripheral tissues, and more recently there has been increased interest in the effects of chronically elevated blood glucose levels on the beta cells. A primary effect of glucotoxicity is reduced insulin secretion, which occurs via hyperglycaemic activation of the UCP2 gene in the beta cell, diverting energy from ATP synthesis and eventually impairing insulin secretion. Insulin secretion may be further Pathophysiological basis for intensive insulin replacement A Rolla reduced by hyperglycaemia-induced apoptosis of beta cells. 22, 27 A growing body of evidence now indicates that early insulin treatment can prolong endogenous insulin secretion to varying degrees in both type I and type II diabetes, promoting better metabolic control. Intensive therapy has also shown value in slowing the progression to frank diabetes in subjects with IGT. Results from the Diabetes Prevention Program indicated that intensive lifestyle intervention and metformin reduced the progression from IGT to diabetes by 58 and 31%, respectively. 28 This suggests that the presence of elevated glucose levels per se accelerates deterioration in glucose control and plays a major role in the transition from IGT to diabetes. 29 In vitro work also suggests that intermittent hyperglycaemia, as occurs when early phase insulin release is impaired in vivo, may be more damaging than chronic low level elevations in fasting blood glucose. 13 
Conclusion
These recent studies highlight the common role of reduced beta-cell function in both type I and type II diabetes, as well as in prediabetic states, the dangers of isolated postprandial glucose elevations in the face of otherwise adequate overall glycaemic control, and the potential benefit of initiating intensive diabetic management as early as possible. Early, intensive insulin treatment offers the most promise for recreating a more normal insulin effect, which is essential for decreasing beta-cell fatigue, maintaining beta-cell secretory capability, stabilising the progression of type II diabetes, enhancing later glycaemic control, and reducing microvascular and macrovascular complications. Until recently, the limitations of conventional basal insulins, such as NPH, have restricted our ability to intensify insulin treatment without undue risk of hypoglycaemia. The advent of newer insulin analogues, with more physiologic pharmacokinetic profiles, offers great promise in overcoming the limitations of older insulin formulations 30, 31 permitting the intensified basal-bolus therapy regimens required to recreate a truly physiological insulin profile.
